Skip to main content
Funded Studies

Evaluation of alpha-synuclein and hemoglobin levels in CSF, plasma and saliva samples from the BioFind cohort

Study Rationale:                   

Alpha-synuclein pathology plays a major role in Parkinson’s disease (PD). Recent studies suggest that measurement of alpha-synuclein in biological fluids (e.g. blood or cerebrospinal fluid) may be a biomarker that can aid in the clinical diagnosis and could help to monitor the progression of the disease. This study aims to measure alpha-synuclein in cerebrospinal fluid, the fluid that surrounds the brain and spinal cord ,  as well as in plasma (derived from blood) and saliva to advance our understanding of the relevance of alpha-synuclein levels as a biomarker for PD. Hemoglobin will be measured as a quality control measure.

Hypothesis:

We hypothesize that alpha-synuclein is present in cerebrospinal fluid, plasma and saliva and that levels can be measured with appropriate assays. We further expect that the amount of alpha-synuclein in biological fluids may be different depending upon the stage of Parkinson’s disease.

Study Design:

Alpha-synuclein and hemoglobin will be analyzed using plate-based immunoassays that utilize a pair of antibodies to measure the levels of each analyte in the appropriate fluid.

Impact on Diagnosis/Treatment of Parkinson’s disease:   Measurement of alpha-synuclein in cerebrospinal fluid, the fluid that surrounds the brain and spinal cord ,  as well as in plasma (derived from blood) and saliva may advance the development of alpha-synuclein levels as a biomarker for PD.

Next Steps for Development:

N/A 

Final Outcome

  


Researchers

  • Peggy Taylor, ScD

    Boston, MA United States


Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.